Biodesix
Biodesix, Inc. is a diagnostic solutions company based in Boulder, Colorado, specializing in blood-based tests for lung cancer and related services. The company offers a range of diagnostic tests, including the Nodify XL2 and Nodify CDT tests, which assist physicians in assessing the risk of malignancy in patients with suspicious lung nodules. Additionally, Biodesix provides tumor profiling and immune profiling tests, such as GeneStrat and VeriStrat, to support timely treatment decisions for oncologists. These tests are processed in a CLIA-certified laboratory, with results typically available within 72 hours. Beyond its diagnostic offerings, Biodesix also engages in clinical research, development, and testing services for biopharmaceutical companies, focusing on the development and commercialization of companion diagnostics to enhance therapeutic efficacy. Established in 2005, Biodesix continues to advance its proprietary mass spectrometry-based discovery platform to improve patient outcomes in lung disease.
Oncimmune
Acquisition in 2019
Oncimmune (USA) LLC, founded in 2006, is a leader in early cancer detection, operating as a subsidiary of Oncimmune LTD based in Nottingham, England. The company specializes in developing proprietary autoantibody assay technologies to identify over 90 percent of solid-tumor cancers, which account for 70 percent of all cancer cases, including those of the lung, breast, colorectal, prostate, stomach, pancreatic, and ovarian cancers. Under the guidance of Dr. John Robertson, the chief scientific officer, Oncimmune focuses on research and development to enhance its diagnostic capabilities. The company's laboratory in metro Kansas City is CLIA-certified, ensuring compliance with regulatory standards for laboratory testing. Oncimmune holds a portfolio of patents that supports its innovative approaches in personalized immunodiagnostics, aimed at improving cancer screening, detection, and patient care.
Integrated Diagnostics
Acquisition in 2018
Integrated Diagnostics Inc. specializes in the development of laboratory-based blood molecular diagnostic tools designed to assist physicians in the early detection of complex diseases through non-invasive blood tests. The company's flagship product, Xpresys Lung, provides objective information for assessing pulmonary nodules by monitoring multiple disease molecular markers simultaneously. Founded in 2005 and based in Seattle, Washington, Integrated Diagnostics aims to leverage emerging technologies to create a pipeline of innovative diagnostic products that facilitate the management of serious conditions such as cancer, diabetes, and Alzheimer's. The company operates under the principle that a systems view of disease, involving networks of proteins, genes, and other molecules, is essential for effective diagnosis and prognosis. Integrated Diagnostics is a subsidiary of Biodesix, Inc. and has established a strategic partnership with Agilent Technologies.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.